Hydrochlorothiazide
Metabolic Syndrome
UMC UtrechtSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 73/ 100
Competitive context
43 Active assets in the Metabolic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax All India Institute of Medical Sciences, Bhubaneswar | Phase 4 | BBB |
Lipitor Seoul National University Hospital | Phase 4 | BBB |
Pioglitazone Philip Kern | Phase 4 | BBB |
Rosuvastatin Dr. B. Catharine. Craven | Phase 4 | BBB |
OLMESARTAN MEDOXOMIL Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Hydrochlorothiazide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →